)
China's Sinovac vaccine has general efficacy of 50.4% in Brazil trials
A coronavirus vaccine developed by China’s Sinovac showed “general efficacy” of 50.38% in a late-stage trial in Brazil.
A coronavirus vaccine developed by China’s Sinovac showed “general efficacy” of 50.38% in a late-stage trial in Brazil.
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)